Woodcliff Lake-based Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., announced Monday it has appointed Michael Amoroso as senior vice president, Americas commercial, oncology business group.
Amoroso, who has over 20 years of experience in the oncology and therapeutics industries, will be responsible for leading Eisai's Americas oncology team and driving commercial strategies for the company's approved products, pipeline assets and late-stage compounds approaching the commercialization stage. He will also serve on the company's Americas executive committee.
"Michael has been tremendously successful in launching oncology brands, developing and collaborating on disease awareness initiatives, repositioning global brand plans, crafting development plans with R&D and medical colleagues, and leading large cross-functional teams in working together to deliver high quality value to customers and patients," said Shaji Procida, CEO and president, Eisai Inc. "We are confident that his extensive experience and proven leadership will help drive the growth of Eisai's oncology business in the Americas."
Prior to Eisai, Amoroso was at Celgene in a variety of marketing roles. Most recently, he served as commercial head, global markets for CAR-T programs. He also held roles in global marketing for the GI Oncology Franchise, and in U.S. oncology marketing. Before Celgene, he served in a number of sales leadership and marketing roles at Sanofi Aventis.